Peptide-Drug Conjugates Advance as Next-Generation Cancer Therapeutics With Six in Phase III
A comprehensive review in Journal of Nanobiotechnology positions peptide-drug conjugates (PDCs) as the next evolution beyond antibody-drug conjugates (ADCs) for targeted cancer therapy. Six PDCs are now in Phase III clinical trials with approximately 96 in development, offering advantages in tissue penetration, lower immunotoxicity, and more accessible manufacturing than ADCs.